OncLive TV

Andrew Kuykendall, MD, explains considerations for JAK inhibitor sequencing and the use of transplant in myelofibrosis.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the potential future utility of PD-L1 expression as a biomarker in EGFR-mutated NSCLC.

Mario Sznol, MD, discusses long-term melanoma survival, treatment gaps after progression, and emerging strategies for resistant disease.

Neil D. Gross, MD, FACS, discusses the importance of year-round vigilance when it comes to skin cancer prevention and education.

Bradley McGregor, MD, discusses the rationale of the STRIKE trial of tivozanib plus pembrolizumab in RCC.

Shubham Pant, MD, MBBS, discusses results from the landmark phase 3 RASolute 302 trial for daraxonrasib in previously treated metastatic PDAC.

Alexey Danilov, MD, PhD, discusses second-line treatment selection for patients with chronic lymphocytic leukemia who have received venetoclax-based regimens.

Mario Sznol, MD, discusses the current therapeutic landscape in the frontline setting for patients with advanced or metastatic melanoma.

Ashley Sumrall, MD, FACP, FASCO, discusses CAR T-cell therapies and BTK inhibitors in primary central nervous system lymphoma and the role they play.

Bradley Monk, MD, FACOG, FACS, discusses the relevance of FRα, HER2, and PD-L1 expression in influencing decision-making in recurrent ovarian cancer.

Mina M. Fam, MD, and Bradley McGregor, MD, discuss the treatment landscape of testicular cancer during Testicular Cancer Awareness Month.

Timothy N. Clinton, MD, discusses initiatives to improve outcomes for female patients with bladder cancer.

Vinayak Venkataraman, MD, discusses how certain biological requirements for emerging cellular therapies could exacerbate racial disparities in sarcoma.

Oncology experts share perspectives and suggest advice for reducing burnout related to conference attendance and taking personal time away from the clinic.

Colton Jones, MD, discusses real-world data comparing GLP-1 receptor agonists and aspirin for the primary prevention of colorectal cancer.

Timothy N. Clinton, MD, discusses biologic and anatomical differences underlying sex and gender disparities in bladder cancer incidence.

Top experts discuss the most important takeaways and data to come out of this year’s SGO Annual Meeting on Women’s Cancer.

Sara M. Tolaney, MD, MPH, discusses how the shifting understanding of HER2 expression in breast cancer may affect the management of this disease.

Timothy N. Clinton, MD, discusses differences between genders in terms of bladder cancer presentation.

Adanma Ayanambakkam, MD, MS, discusses the safety profile of darlifarnib plus cabozantinib in ccRCC.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the future for evaluating PD-L1 expression as a biomarker in EGFR-mutated NSCLC.

Brian M. Wolpin, MD, MPH, discusses phase 1/2 data showing high activity with daraxonrasib in first-line metastatic pancreatic ductal adenocarcinoma.

Sara M. Tolaney, MD, MPH, discusses how the early-stage HER2-positive breast cancer treatment paradigm is evolving with the emergence of new phase 3 data.

Rena D. Callahan, MD, discusses the clinical utility and shifting paradigms of oral SERDs for patients with ER-positive advanced breast cancer.

Sara M. Tolaney, MD, MPH, discusses how therapeutic strategies are evolving within the HER2-positive breast cancer treatment paradigm.

Rena D. Callahan, MD, notes the implications of adding camizestrant to an aromatase inhibitor in ER-positive breast cancer with an emergent ESR1 mutation.

Jesús Berdeja, MD, discusses the optimal timing of CAR T-cell therapy referral for patients with multiple myeloma.

Adanma Ayanambakkam, MD, MS, discusses efficacy data from the phase 1a/1b FIT-001 trial.

Adanma Ayanambakkam, MD, MS, discusses the mechanism of action of darlifarnib in ccRCC.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, note data from a study of PD-L1 expression as a marker of response to TKIs in EGFR-mutated NSCLC.